You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. XRpro Radioactive Cesium Decorporation Agents

    SBC: Icagen, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Caldera aims to develop an inexpensive stable selective decorporation decorp agent for cesium Cs Cs is easily obtainable by terrorists and treatments for exposures are Project Bioshield priorities for use in radiation nuclear emergencies high priority for DHHS NIH NIAID DAIT and a critical need for the Strategic National Stockpile S ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Cell therapy for Repairing Warm Ischemically Damaged Kidneys

    SBC: BREONICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this project is address a large unmet medical need by providing more kidneys for transplant For the andgt patients with end stage renal disease in the U S the pool of cadaveric kidneys has remained stagnant over the past decade As a result the dialysis population is expected to reach andgt million patients in the next decade at an aggr ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology

    SBC: Codagenix Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine

    SBC: AVATAR MEDICAL, LLC            Topic: NIAID

    DESCRIPTION provided by applicant The pre fusion conformation of the RSV F protein preF is the primary determinant of neutralization in immunized sera However this conformation is unstable and rapidly transitions to the postfusion conformation A disulfide stabilized prefusion variant with cavity filling mutations DS Cav has been shown to yield high neutralizing titers in animals howeve ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Recombinant Protein for Mitigating Total Body Radiation Injury

    SBC: THERASOURCE, LLC            Topic: NIAID

    DESCRIPTION provided by applicant This SBIR Phase I proposal is intended to demonstrate the feasibility of developing a novel and effective therapeutic agent for acute radiation injury The threat of nuclear terrorism remains high and there is a possibility of a nuclear power plant leak both of which can cause acute radiation injury at a large scale Currently there are no therapeutic agents ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Single-chain antibody countermeasures for the Radiation GI Syndrome

    SBC: CERAMIDE THERAPEUTICS, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Genetic or pharmacologic inhibition of ceramide mediated cell death within the vascular endothelium of the gastrointestinal tract GI protects mice from death from the Radiation GI Syndrome RGS Prophylactic administration of anti ceramide antibody attenuates endothelial apoptosis resulting in significant protection of intestinal stem cells and animal survi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Ultra-low dose Influenza vaccines

    SBC: Codagenix Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Current seasonal Influenza vaccines are proving to be ineffective especially in at risk populations For example this yearandapos s inactivated flu vaccine had only a efficacy rate against H N infections in the elderly and the current live attenuated Influenza vaccine LAIV is aged restricted for those above years of age Therefore there is glaring un ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Enhancing engraftment of cord blood for treatment of neoplastic disorders

    SBC: Marrowsource Therapeutics International LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Hematopoietic stem cell transplantation is a form of stem cell therapy used to treat cancers such as lymphoma and leukemia and other blood related diseases However there currently are several drawbacks in the use of bone marrow hematopoietic cell transplantation Most importantly the donor pool is limited by the need for at least partial HLA matching and t ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government